Rigetti Computing Inc Q3 FY2025 Revenue Increased 18.4% YoY, Largest Change in Net Loss in 2025

Executive Summary

Rigetti Computing Inc (Ticker: RGTI) reported its Q3 FY2025 financial results, demonstrating a significant increase in revenue compared to the same period last year, with an 18.4% rise from $1.647 million in Q3 FY2024 to $1.947 million in Q3 FY2025. The company’s net loss widened substantially, reaching $200.968 million, reflecting increased investment in R&D and operational expenses. Cash and cash equivalents decreased by 61.4% from $67.674 million to $26.133 million, indicating ongoing capital deployment to support growth initiatives. The gross profit declined to $404,000 from $1.204 million YoY, while operating expenses surged, notably in R&D and SG&A. The company’s total assets increased to $630.274 million, primarily driven by higher investments and intangible assets, while liabilities grew to $258.448 million, mainly due to derivative warrant liabilities and earn-out obligations. The financials highlight a strategic focus on scaling quantum computing capabilities amid macroeconomic and market challenges, with a cautious outlook on liquidity and profitability.

Management Discussion and Analysis (MD&A)

During Q3 FY2025, Rigetti continued to invest heavily in quantum hardware development and platform expansion, reflected in a 31.4% increase in R&D expenses to $15.02 million from $12.75 million YoY. Revenue growth was driven by increased access to quantum systems and collaborative research services, with revenue from these segments rising by 18.4%. Despite revenue growth, gross margins remained compressed at 20.7%, impacted by higher costs associated with scaling manufacturing and operational infrastructure. The net loss expanded by 35.7%, primarily due to a significant increase in derivative warrant liabilities, which surged by 130.4% to $214.3 million, reflecting fair value adjustments linked to warrant exercises and market volatility. Cash burn rate remained high, with net cash used in operating activities totaling $43.642 million for the nine months, emphasizing the need for additional capital or strategic partnerships. The balance sheet shows a robust investment portfolio, with short-term U.S. treasury securities valued at $420.85 million, supporting liquidity. Management remains committed to advancing quantum technology while managing liquidity risks, with plans to optimize capital structure and explore strategic collaborations to accelerate commercialization.

Income Statement Analysis

Revenue for Q3 FY2025 increased by 18.4% YoY from $1.647 million to $1.947 million, driven by higher system access and research services. Gross profit declined to $404,000 from $1.204 million, resulting in a gross margin of 20.7%, down from 50.7% YoY, due to increased manufacturing and operational costs. Operating expenses surged to $20.95 million from $18.55 million, with R&D expenses rising by 17.8% and SG&A increasing by 2.4%, reflecting ongoing investments in product development and market expansion. The operating loss widened to $20.549 million from $17.346 million YoY. Net loss for the quarter was $200.968 million, compared to a loss of $14.833 million in the same period last year, with the increase primarily attributable to a fair value loss of $162.8 million on derivative warrants, compared to a gain of $0.5 million YoY. Earnings per share (EPS) were negative $0.62 basic and diluted, consistent with the prior year’s loss per share of $0.08. The YoY deterioration underscores the company’s strategic focus on long-term growth despite short-term profitability challenges.

Balance Sheet Analysis

As of September 30, 2025, Rigetti’s total assets increased to $630.274 million from $284.788 million at December 31, 2024, driven by a substantial rise in investments and intangible assets. Cash and cash equivalents decreased by 61.4% to $26.133 million, reflecting capital deployment in R&D and infrastructure. Available-for-sale investments in short-term U.S. treasury securities increased to $420.85 million, providing liquidity buffer. Total liabilities grew to $258.448 million from $158.198 million, mainly due to derivative warrant liabilities ($214.3 million) and earn-out liabilities ($0.0 after settlement). Stockholders’ equity increased to $371.826 million from $126.589 million, primarily due to issuance of new shares and accumulated comprehensive income. The company’s leverage remains moderate, with a debt balance of $9.5 million fully prepaid in December 2024, and no significant short-term debt obligations. Liquidity remains a key focus, with available cash and investments supporting operations for at least the next 12 months, but profitability remains elusive amid high R&D and market expansion costs.

Cash Flow Analysis

For the nine months ended September 30, 2025, net cash used in operating activities was $43.642 million, primarily due to net loss adjustments and increased working capital investments. Cash flows from investing activities were negative at $389.708 million, mainly from purchases of available-for-sale securities ($522.605 million) and property and equipment ($14.103 million). Cash flows from financing activities totaled $391.912 million, driven by proceeds from the sale of common stock through ATM offerings ($346.719 million), private placements ($35 million), and stock options exercises ($1.81 million). The company prepaid all outstanding debt of $9.5 million in December 2024, eliminating interest expenses in subsequent periods. Overall, cash burn remains high, emphasizing the need for strategic capital management and potential fundraising to sustain long-term R&D efforts and market expansion initiatives.

Ratios & DuPont Analysis

Net profit margin remains negative at -10,340%, reflecting high operating costs and warrant-related fair value losses. Return on assets (ROA) is -31.9%, indicating significant asset utilization inefficiency amid ongoing investments. Return on equity (ROE) is -54.2%, driven by accumulated deficits and net losses. Asset turnover ratio is 0.003, showing low revenue generation relative to total assets, while the equity multiplier is 1.69, indicating moderate leverage. The DuPont analysis underscores the company’s early-stage growth phase, with high R&D intensity and market risk, but also substantial asset base and investor support through equity issuance.

Risk Factors

Rigetti faces several risks including technological development delays, market competition from larger quantum players, regulatory uncertainties, and macroeconomic volatility impacting funding and customer adoption. The company’s high leverage on warrants and earn-out liabilities introduces valuation and market risks, especially given the fair value fluctuations. Liquidity constraints and high R&D expenses pose ongoing operational risks, requiring strategic capital raising and cost management. External factors such as geopolitical tensions, supply chain disruptions, and macroeconomic downturns could further impact growth prospects and financial stability.

Notes & Additional Commentary

The quarter was marked by a significant fair value loss on derivative warrants, reflecting market volatility and warrant exercise activity. The company’s strategic investments in quantum hardware and platform expansion continue, with a focus on long-term technological leadership. Unusual items include a substantial increase in warrant liabilities and earn-out obligations, which are market-driven and non-cash in nature. The company’s liquidity position remains adequate for the near term, but profitability remains a key challenge. Management is exploring strategic partnerships and capital markets to support ongoing R&D and commercialization efforts.

Investment Implications

In the short term, investors should monitor the company’s ability to manage warrant-related fair value fluctuations and liquidity risks. The significant increase in R&D expenses and net losses suggests a high-risk, high-reward profile aligned with early-stage quantum technology development. Long-term investors may find value in Rigetti’s technological potential and strategic collaborations, but should remain cautious of market volatility and execution risks. A balanced approach considering both growth opportunities and operational challenges is recommended, with attention to capital raising plans and market conditions.